SCHEMBL11946802

SCHEMBL11946802

CC(C)(C)c1ccc(CCOc2nc(O)nc3ccccc23)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.39
MAPT P10636 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
PPARG P37231 2/20 0.39
PPARA Q07869 1/20 0.39
HRH4 Q9H3N8 1/20 0.39
PPARD Q03181 1/20 0.39
ESRRG P62508 2/20 0.39
ABCG2 Q9UNQ0 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
TP53 P04637 3/20 0.38
TNKS O95271 1/20 0.37
TNKS2 Q9H2K2 1/20 0.37
ACKR3 P25106 2/20 0.37
GAA P10253 1/20 0.37
CYP2C19 P33261 1/20 0.37
PDE5A O76074 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11938502 0.85 PPARG (0.39) POLBMAPTMEN1KMT2APPARG
SCHEMBL3847720 0.85 PPARG (0.39) POLBMAPTMEN1KMT2APPARG
SCHEMBL11946803 0.85 HRH4 (0.39) POLBMAPTMEN1KMT2ATSHR
SCHEMBL8547647 0.83 CCNB2 (0.43) POLBMAPTMEN1KMT2APPARG
Fenazaquin SCHEMBL29429249 0.81 RAB9A (0.54) POLBMAPTMEN1KMT2ATSHR
Fenazaquin SCHEMBL26216 0.81 RAB9A (0.54) POLBMAPTMEN1KMT2ATSHR
Fenazaquin SCHEMBL27889647 0.80 RAB9A (0.52) POLBMAPTMEN1KMT2ATSHR
Fenazaquin SCHEMBL3989654 0.75 RAB9A (0.44) POLBMAPTMEN1KMT2ATSHR
SCHEMBL8547995 0.74 RAB9A (0.52) POLBMEN1KMT2ATSHRSMN1; SMN2
SCHEMBL8547053 0.73 RAB9A (0.51) POLBMEN1KMT2ATSHRHRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8226929-B2 Administering to a patient a contrast agent (pyridimifen, fenazaquin) which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging LANTHEUS MEDICAL IMAGING, INC. (US) 2012-07-24 US disclosed
US-20080112884-A1 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING BRISTOL-MYERS SQUIBB PHARMA COMPANY 2008-05-15 US disclosed
US-7344702-B2 Contrast agents for myocardial perfusion imaging BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080112884-A1 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING TNNI3, TNNT2, FABP3 POLB 2251/4885MAPT 4043/4885MEN1 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.